Skip to main content
Fig. 3 | BMC Nephrology

Fig. 3

From: Effect of the combination of bumetanide plus chlorthalidone on hypertension and volume overload in patients with chronic kidney disease stage 4–5 KDIGO without renal replacement therapy: a double-blind randomized HEBE-CKD trial

Fig. 3

Effects on blood pressure. The bumetanide plus placebo group is shown in blue (control group), and the bumetanide plus chlorthalidone group is shown in red (intervention group). A There was a decrease in SBP on Day 7 [intervention: -18 (95% CI, -25.2 to -10.5) vs. control: -7.5 (95% CI, -17 to 2), p = 0.073] and Day 30 [intervention: -26.1, 95% CI, -34.3 to -18.1, vs. control: -10 95% CI, -34.3 to -18.1; p = 0.028]. B There was a reduction in DBP on Day 7 (intervention: -8.5, 95% CI, -13.4 to -3.5, vs. control: -2.25, 95% CI, -6.8 to 2.3, p = 0.059) and Day 30 [intervention: -13.5 (95% CI, -19.2 to -7.7) vs. control: -3.4 (95% CI, -9.7 to -2.9), p = 0.018]. C There was a decrease in MAP on Day 7 (intervention: -11.7, 95% CI, -16.4 to -7.1, vs. control: -3.9, 95% CI, -9.4 to 1.5, p = 0.029) and Day 30 (intervention: -18.1, 95% CI, -22.8 to -13.4, vs. control: -5.4 95% CI, -13 to 2.2, p = 0.005)

Back to article page